吉西他滨联合奥沙利铂、特瑞普利单抗治疗肝内胆管细胞癌术后合并脾脏转移致血小板减少症1例  

A Case Report of Gemcitabine Combined with Oxaliplatin and Toripalimab in the Treatment of Thrombocytopenia Caused by Splenic Metastasis after Surgery for Intrahepatic Cholangiocarcinoma

作　　者：刘耀兴 陈利霞[1] 段春霞[1] 陈晓娟 LIU Yao-xing;CHEN Li-xia;DUAN Chun-xia;CHEN Xiao-juan(Cancer Center,the First Affiliated Hospital of Baotou Medical College,Baotou 014010,China;Baotou Center for Disease Control and Prevention,Baotou 014030,China)

机构地区：[1]包头医学院第一附属医院肿瘤中心,包头014010 [2]包头市疾病预防控制中心,包头014030

出　　处：《中国合理用药探索》2024年第5期25-28,共4页Chinese Journal of Rational Drug Use

摘　　要：肝内胆管细胞癌(ICC)是原发性肝癌的一种类型。本文报道了1例ICC术后合并脾脏转移维持化疗的63岁男性患者,该患者联合应用吉西他滨+奥沙利铂+特瑞普利单抗治疗,并在化疗周期内出现白细胞计数和血小板计数减少的情况。给予人粒细胞刺激因子注射液治疗后,白细胞计数增加,血小板计数进一步减少;对症给予重组人血小板生成素注射液治疗,血小板计数增加。对于晚期ICC患者,临床医生可根据专家指南与共识给予患者合适的对症治疗,以延长患者生存期。Intrahepatic cholangiocarcinoma(ICC)is a type of primary liver cancer.This report details a case of splenic metastasis after surgery for ICC in a 63-year-old male patient on maintenance treatment,who was treated with combination therapy with gemcitabine+oxaliplatin+toripalimab and showed decreased white blood cell count and reduced platelet count during the chemotherapy cycle.The patient showed increased white blood cell count and further reduced platelet count in response to treatment with recombinant human granulocyte colony-stimulating factor injection,and showed increased platelet count after symptomatic treatment with recombinant human thrombopoietin injection.For patients with advanced ICC,clinicians may provide appropriate symptomatic treatment according to expert guidelines and consensus,so as to prolong the survival time of patients.

关 键 词：肝内胆管细胞癌 吉西他滨 奥沙利铂 特瑞普利单抗 血小板减少 

分 类 号：R979.1[医药卫生—药品]